Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D.

Breast Cancer Res Treat. 2007 Sep;105(1):17-28. Epub 2006 Nov 17.

PMID:
17111207
2.

A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer.

Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL.

Breast Cancer Res Treat. 2010 Feb;120(1):111-8. doi: 10.1007/s10549-009-0678-5.

PMID:
20054647
3.

Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells.

Fong S, Shoemaker M, Cadaoas J, Lo A, Liao W, Tagliaferri M, Cohen I, Shtivelman E.

Cancer Biol Ther. 2008 Apr;7(4):577-86. Epub 2008 Jan 7.

PMID:
18305410
4.

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.

Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schöffski P.

Invest New Drugs. 2008 Oct;26(5):483-8. doi: 10.1007/s10637-008-9131-6. Epub 2008 Apr 19.

PMID:
18425418
5.

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Steinberg M.

Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Review.

PMID:
18840366
6.

A Phase 2 study of perifosine in advanced or metastatic breast cancer.

Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, Moore MJ.

Breast Cancer Res Treat. 2008 Mar;108(1):87-92. Epub 2007 Apr 26.

PMID:
17458693
7.

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.

Smith JW 2nd, McIntyre KJ, Acevedo PV, Encarnacion CA, Tedesco KL, Wang Y, Asmar L, O'Shaughnessy JA.

Breast Cancer Res Treat. 2009 Nov;118(2):361-7. doi: 10.1007/s10549-009-0410-5. Epub 2009 May 21.

PMID:
19459042
8.

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J.

Lung Cancer. 2008 Jul;61(1):82-90. doi: 10.1016/j.lungcan.2007.12.011. Epub 2008 Feb 5.

PMID:
18255187
9.
10.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
11.

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.

O'connor T, Rustum Y, Levine E, Creaven P.

Cancer Chemother Pharmacol. 2008 Jan;61(1):125-31. Epub 2007 Apr 11.

PMID:
17426973
13.

BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.

Marconett CN, Morgenstern TJ, San Roman AK, Sundar SN, Singhal AK, Firestone GL.

Cancer Biol Ther. 2010 Aug 15;10(4):397-405. Epub 2010 Aug 20.

14.

Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.

Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD.

Lung Cancer. 2008 Jun;60(3):374-80. Epub 2007 Dec 3.

PMID:
18054408
15.

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.

Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M.

Lung Cancer. 2009 Apr;64(1):60-5. doi: 10.1016/j.lungcan.2008.06.017. Epub 2008 Aug 9.

PMID:
18692272
16.

Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.

Eichbaum MH, Schuetz F, Khbeis T, Lauschner I, Foerster F, Sohn C, Schneeweiss A.

Anticancer Drugs. 2007 Sep;18(8):963-8.

PMID:
17667603
17.

A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.

Blakely LJ, Buzdar A, Chang HY, Frye D, Theriault R, Valero V, Rivera E, Booser D, Kuritani J, Tsuda M.

Clin Cancer Res. 2004 Aug 15;10(16):5425-31.

18.

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW.

J Clin Oncol. 2008 Jun 20;26(18):2999-3005. doi: 10.1200/JCO.2007.14.0590. Epub 2008 May 5.

PMID:
18458039
19.

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.

Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K, Karaseva V, Tjulandin S.

Breast Cancer Res Treat. 2008 Jul;110(2):309-15. Epub 2007 Sep 13.

PMID:
17851759
20.

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.

Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP.

Cancer. 2009 Jun 1;115(11):2438-46. doi: 10.1002/cncr.24280.

Supplemental Content

Support Center